

2015

Is Myeloproliferative Neoplasm with Splanchnic Vein Thrombosis a Distinct Clinical Entity?

Upasana Joneja, MD

Thomas Jefferson University Hospital, Philadelphia, PA, upasana.joneja@jefferson.edu


Jerald Z. Gong, MD

Thomas Jefferson University, Jerald.Gong@jefferson.edu

Guldeep Uppal, MD

Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Guldeep.Uppal@jefferson.edu

Let us know how access to this document benefits you

Follow this and additional works at: <http://jdc.jefferson.edu/pacbresidentposters> Part of the [Medical Anatomy Commons](#), [Medical Cell Biology Commons](#), and the [Medical Pathology Commons](#)

Recommended Citation

Joneja, MD, Upasana; Gong, MD, Jerald Z.; and Uppal, MD, Guldeep, "Is Myeloproliferative Neoplasm with Splanchnic Vein Thrombosis a Distinct Clinical Entity?" (2015). *Pathology, Anatomy and Cell Biology Resident's Posters*. Paper 15.

<http://jdc.jefferson.edu/pacbresidentposters/15>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Pathology, Anatomy and Cell Biology Resident's Posters by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Is Myeloproliferative Neoplasm with Splanchnic Vein Thrombosis a Distinct Clinical Entity?

Upasana Joneja MD, Jerald Z. Gong MD, Guldeep Uppal MD
Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania

CLINICAL HISTORY

A 29 year-old previously healthy female presented with sub-acute symptoms of weight loss, right upper quadrant pain and nausea.

CBC results: WBC-11.7, Hb- 12.5, Platelet- 286, MCV- 90, MCV- 26.8, RDW- 18%.

Imaging: Ultrasound and MRI of the abdomen were suggestive of Budd-Chiari syndrome that was supported by a liver biopsy showing features of hepatic outflow obstruction (Figure 1). There was no clinical or radiological evidence of splenomegaly. The hypercoagulable work-up was negative. An underlying Myeloproliferative Neoplasm (MPN) was suspected.

BONE MARROW FINDINGS








Figure 2. A) Bone marrow core biopsy showing 75% cellularity, 20x B) Clustering of megakaryocytes, 200x C) Diffuse increased reticulin fibrosis, 100x D) Myeloid cells highlighted with immunostain CD33, 100x E) Glycophorin-A immunostain showing mild increase in erythroid lineage (decreased M: E ratio).

IMAGING




Figure 1. A) Doppler ultrasound of the liver showing patent right and left hepatic veins, with middle hepatic vein outflow obstruction B) Liver, MRI showing hepatomegaly (caudate lobe), peripheral fibrosis and edema consistent with subacute Budd-Chiari syndrome C) Histology of the liver consistent with outflow obstruction


FINAL DIAGNOSIS: MYELOPROLIFERATIVE NEOPLASM, POLYCYTHEMIA VERA, CO-EXISTING WITH IRON DEFICIENCY, JAK2+ (ASSOCIATED WITH SPLANCHNIC VEIN THROMBOSIS)

- Normocellular bone marrow with reduced myeloid to erythroid ratio (1:1)
- Erythroid lineage with left shifted maturation.
- Abnormal proliferation and clustering of megakaryocytes
- The background showed mild diffuse reticulin fibrosis.

(See Figure 2)

CYTOGENETICS

Complex karyotype, bone marrow:
46,XX,+1,del(1)(p13), del(1)(q25),-20 [11] / 49, idem,+del(1)(p13), +8,+9[9]



FOLLOW-UP LABORATORY STUDIES

- Erythropoietin level- 13.5 mIU/ml (normal)
- LDH level- 213 IU/L (normal)
- Iron studies: Serum iron- 39 mcg/dL (low), Iron saturation- 8% (low), Iron binding capacity 494 mcg/dL (high), Serum ferritin 14 ng/mL (low)
- Molecular testing (Real time quantitative PCR, peripheral blood sample): Positive for JAK-2 V617F mutation; Negative for BCR/ABL1

DISCUSSION

MPNs comprise of two categories- BCR-ABL1 positive MPN or chronic myeloid leukemia and BCR-ABL1 negative MPNs that include polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Ten percent of the patients who present with splanchnic vein thrombosis (SVT) have an underlying occult or overt MPN. These patient histories are often complicated by iron deficiency due to thrombosis and bleeding, which may result in normal hemoglobin and/or platelet levels. The hypercoagulable state of polycythemia vera is likely a direct result of the JAK2 mutation. As a consequence of mutated JAK2 function, there is a generalized hypersensitivity to cytokines, with over-expression of pro-coagulant factors and adhesion molecules at the vascular wall. Of note, JAK2 exon 12 and MPL515 mutations are extremely rare in SVT.

A recent meta-analysis has suggested that patients with MPNs associated with thrombosis in hepatic veins, and/or portal veins are possibly a distinct clinical category than patients with MPNs without thrombotic complications (*Leukemia research* 2015;(39):525-529). The clinico-pathologic features of the former group have been recently characterized and include younger age at presentation, female predominance and normal peripheral cell counts as seen in our patient. As these patients often present with normal hemoglobin and/or platelet count due to bleeding/thrombosis and iron deficiency, a JAK2 analysis and bone marrow biopsy evaluation should always be considered a key component of the diagnostic algorithm. Even these studies are sometimes not enough to distinguish between various MPN entities and a comprehensive approach is necessary for reaching a diagnosis.